HBV RNAi inhibitor RG6346 in Phase 1b-2a trial was safe, well-tolerated, and resulted in substantial and durable reductions in serum HBsAg levels

Conference Reports for NATAP

The Liver Meeting
Digital Experience
AASLD
November 13 - 16 - 2020


HBV RNAi inhibitor RG6346 in Phase 1b-2a trial was safe, well-tolerated, and resulted in substantial and durable reductions in serum HBsAg levels

	AASLD 2020 Nov 11-16 Late Breaker Prof. Man-Fung Yuen, M.D., Ph.D., D.Sc. Queen Mary Hospital, The University of Hong Kong, Hong Kong